FORT WORTH, Texas, Jan. 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing…
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T…
Novel HIV vaccine candidate based on Gorilla adenoviral vector (GRAd-HIV) funded by the Bill & Melinda Gates Foundation to alleviate…
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the…
- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine…
SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to…
AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker…
EMERYVILLE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop…
BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…
VANCOUVER, British Columbia, and BASEL, Switzerland, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company…